Cabopol Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions
- Product Name: Cabopol Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions
- Factroy Site: Yudu County, Ganzhou, Jiangxi, China
- Price Inquiry: sales10@sinochem-nanjing.com
- Manufacturer: Ascent Petrochem Holdings Co., Limited
- CONTACT NOW
- Cabopol Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is typically used in formulations when pH and viscosity must be controlled within specific ranges.
| HS Code | 857852 |
| Product Name | Cabopol Veterinary Grade API |
| Api Name | Cabopol |
| Api Type | Active Pharmaceutical Ingredient (API) |
| Grade | Veterinary |
| Intended Administration Forms | Tablets, Injections, Capsules, Powders, Granules, Premix, Solutions |
| Quality Standard Basis | To be confirmed by supplier's Certificate of Analysis (COA) |
| Storage And Shelf Life | Refer to supplier COA/MSDS |
As an accredited Cabopol Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Packaged in sealed, light-resistant, tamper-evident containers suitable for veterinary API formulations. Supplied in quantities from 100 g to 25 kg for flexible manufacturing. |
| Container Loading (20′ FCL) | A 20′ FCL container loaded with Cabopol veterinary-grade API, packaged in sealed pharmaceutical-grade drums, safely secured, labeled, and documented for transport. |
| Shipping | Cabopol Veterinary Grade API is shipped in sealed, labeled containers complying with international hazardous-material regulations. Shipments include safety data sheets and tamper-evident packaging to prevent contamination. Temperature-controlled logistics maintain stability during transit. Dry, ventilated storage away from incompatible substances is required. Delivery documentation confirms product identity, batch number, and regulatory compliance. |
| Storage | Store Cabopol Veterinary Grade API in tightly sealed, original containers away from moisture, direct sunlight, and heat. Maintain a cool, dry environment between 15–30°C. Protect from humidity and incompatible substances. Ensure good ventilation and keep containers closed when not in use. Use within expiry date, following manufacturer guidelines for all dosage forms. |
| Shelf Life | Shelf life is 24 months from manufacture date when stored in original, tightly sealed containers under recommended conditions. |
In drinking-water medication systems where oral solutions are dosed through proportioner pumps at 1–5% stock dilution, Cabopol Veterinary Grade API is first hydrated as a separate gel phase rather than dry-blended into the final tank. A 0.15–0.40% w/w dispersion is prepared in cold purified water at 15–25°C using a rotor-stator mixer at 800–1,200 rpm for 45–60 min; the acidic dispersion remains low-viscosity until neutralisation with 18% w/w sodium hydroxide solution to pH 6.8–7.4. Under these conditions the polymer chains swell to a pseudoplastic gel with a Brookfield RVT viscosity of 4,000–15,000 cP measured at 20 rpm with spindle 6 at 25°C, as specified under Ph. Eur. 2.2.8. If the final drinking water contains electrolytes above 0.9% w/v sodium chloride or bicarbonate, the gel is diluted after neutralisation and mixed for 15–20 min; charge screening by monovalent ions reduces yield value, and the polymer concentration is raised by 0.05–0.10% w/w per 100 mEq/L added ionic strength. Finished oral solutions are filtered through 500 µm mesh filters before filling; pH is rechecked after 24 h because carbomer dispersions can undergo slight alkaline hydrolysis at room temperature above pH 8.0, with a viscosity loss of 5–15% over 30 days at 25°C. Packaging in HDPE drums or opaque polyethylene totes is used because light exposure is associated with free-radical oxidative chain scission in non-stabilised grades; the addition of 0.05% w/w disodium EDTA is routine in hard-water systems above 300 ppm CaCO₃ to prevent calcium bridging of carboxylate groups. Cationic preservatives such as benzalkonium chloride are avoided above 0.01% w/w because they interact with carboxylate groups and can form coacervates. The finished product is tested for pH (Ph. Eur. 2.2.3), viscosity (Ph. Eur. 2.2.8), and microbial enumeration (Ph. Eur. 2.6.12) before release as a non-sterile oral liquid for cattle, swine, and poultry.
What limits terminal sterilisation of a carbomer-adjuvanted injectable?
Injectable suspensions and inactivated vaccines require a gel adjuvant that can be sterilised without destroying antigenicity; Cabopol Veterinary Grade is evaluated at 0.2–0.5% w/v in phosphate-buffered saline pH 6.5–7.5. The dispersion is hydrated under aseptic conditions with a high-shear mixer at 1,000–1,500 rpm for 60 min, then neutralised with 0.1 N sodium hydroxide and autoclaved only if the formulation has been validated for terminal sterilisation; steam sterilisation at 121°C for 15 min has been reported to reduce apparent viscosity by 40–60% in carbomer gels due to hydrolytic cleavage of the polyacrylic backbone, so aseptic filtration of the non-gelled acidic dispersion followed by neutralisation is used for heat-sensitive antigens. The particulate size must be controlled after neutralisation by laser diffraction (ISO 13320) to a D90 below 20 µm to minimise injection-site reactions in intramuscular administration; the final product is not intended for intravenous use because the gel network can occlude small capillaries in pulmonary or renal beds. Endotoxin load is monitored by USP <85> with an acceptance criterion of <0.5 EU/mg for parenteral-grade polymer, and sterility is confirmed by USP <71> membrane filtration. Residual acrylic acid monomer is held below the Ph. Eur. carbomer monograph limit, typically 0.25% w/w, and residual allyl pentaerythritol ether is controlled because these species may contribute to local irritation. Batch-to-batch variation in neutralisation kinetics is managed by adding sodium hydroxide at 2–5 mL/min under continuous pH monitoring; if the target pH is overshot above 7.8, the gel becomes stringy and cannot be reprocessed without shearing the polymer chains. Adjuvant activity is likely mediated by antigen retention at the injection site, but published data for this specific configuration in all veterinary species is limited; manufacturers validate target animal safety per VICH GL44 and serological response per 9 CFR 113 protocols rather than relying on a single viscosity specification.
High-dose ruminant boli and tablets with drug load above 40% w/w are formulated with Cabopol Veterinary Grade as a dry binder and controlled-release matrix former at 5–15% w/w in a direct compression or wet granulation line. Direct compression on a rotary press with 20–35 kN main compression force produces tablets with breaking force 8–15 kP when the polymer is pre-blended with microcrystalline cellulose and lactose; the polymer’s plastic deformation under load reduces friability to <0.8% by USP <1216>. Wet granulation with purified water is used for formulations containing hygroscopic salts or ionophores because the carbomer hydrates partially in the granulator and forms a gel bridge between drug and filler particles; the granulation endpoint is controlled by impeller power consumption on a high-shear mixer at 150–250 RPM and chopper speed 1,000–1,500 RPM, with water addition at 10–15% w/w of dry mass. The wet mass is passed through a 2.0 mm screen and dried in a fluid-bed dryer at inlet air temperature 45–55°C until loss on drying is 1.5–2.5% w/w; higher moisture above 3.0% w/w causes picking during compression and increases tablet weight variability. The final tablets are coated with a 5–10% w/w aqueous film coat; because carbomer swells upon contact with gastric fluid, rapid tablet disintegration can be delayed for 30–120 min depending on the matrix level. Dissolution is tested by USP Apparatus II at 50 rpm in 900 mL of 0.1 N hydrochloric acid or pH 6.8 phosphate buffer; f2 similarity is calculated against the reference product. Batch records include checks for residual water, breakage force, and content uniformity per Ph. Eur. 2.9.40 or USP <905>.
Capsule fill weight drift after uncontrolled granule moisture
Capsule formulations containing Cabopol Veterinary Grade are processed as multiparticulates because direct filling of the dry powder into hard gelatin capsules produces static adhesion, flow angle above 40°, and capsule weight variation greater than 5%. The granules are prepared by extrusion-spheronization with 30–50% w/w microcrystalline cellulose, 10–20% w/w lactose monohydrate, and 5–10% w/w Cabopol Veterinary Grade, wetted to 35–45% w/w water in a low-shear planetary mixer. Extrudate is passed through a 0.8–1.2 mm screen on a twin-screw extruder with L/D ratio 20:1 at screw speed 50–80 rpm, then spheronised at 400–800 rpm for 3–6 min. Drying to 1.0–2.0% w/w moisture is critical; if residual moisture exceeds 2.5% w/w, the granules soften on storage and the capsule fill weight drifts by more than 3–5% on a dosator-type automatic filler. The finished capsules are tested for dissolution by USP <711> and for moisture by Ph. Eur. 2.2.32. In veterinary capsule products where split dosing to small animals is required, the polymer level is reduced to 2–5% w/w because higher levels create a gel plug that delays release beyond 60 min in simulated gastric fluid.
In dry oral powders for reconstitution, Cabopol Veterinary Grade is applied at 0.2–0.6% w/w as a suspending agent that hydrates only after the powder is added to water. The powder blend is prepared in a V-blender or bin blender with dextrose, sodium citrate dihydrate, and flavour; the carbomer is pre-screened through a 500 µm mesh to break agglomerates. Mixing time is limited to 10–15 min at 10–15 RPM because prolonged dry mixing builds electrostatic charge and reduces bulk density. The final powder is filled into aluminium foil sachets or HDPE bottles with desiccant to keep moisture specification below 1.5% w/w; if moisture exceeds 2.0% w/w, the carbomer swells on the surface and reconstitution time increases from 5 min to more than 30 min. At the point of use, the powder is added to 20–25°C water under stirring; the suspension is brought to pH 6.5–7.0 with the citrate buffer system, avoiding alkaline overshoot. The reconstituted product is used within 7 days when stored at 2–8°C; viscosity loss after 14 days at 25°C is typically 10–20%, and microbial quality is assessed by Ph. Eur. 2.6.12 and 2.6.13.
When granule particle size distribution shifts above 850 µm
Granules for in-feed or top-dress medication use Cabopol Veterinary Grade as a binder and hydration modifier at 1–3% w/w of the dry granule mass. The granulation fluid is a 10–20% w/w aqueous dispersion of the polymer, prepared separately and added slowly to a fluid-bed granulator at spray rate 20–40 g/min and inlet air temperature 50–60°C. The endpoint is monitored by particle size rather than moisture alone; when the D90 exceeds 850 µm, drug distribution in the finished granule becomes non-uniform because larger granules contain disproportionately more binder-rich shell material. Sieve analysis after drying is performed according to Ph. Eur. 2.9.12; product is considered acceptable when 90% w/w passes 1.0 mm and is retained on 150 µm. The dried granules are packaged in moisture-barrier bags; dusting is assessed by a 75 µm sieve transfer test, and retained dust below 2.0% w/w is typical because the polymer imparts a smooth granule surface. For oral paste granulates, a higher polymer level of 4–6% w/w is used to produce a shear-thinning paste when the granules are mixed with glycerol and water at the time of administration; the paste thixotropy is measured by a cone-plate rheometer at 25°C with a shear rate sweep from 0.1 s⁻¹ to 100 s⁻¹.
Premix segregation control in low-drug-load oral powders
At 0.05–0.25% w/w, Cabopol Veterinary Grade is incorporated into medicated premixes for drinking water or oral drench reconstitution in a carrier of dextrose, sodium chloride, and sodium citrate. Segregation is controlled by matching the bulk density of the carbomer phase to the carrier; pre-blending the polymer with 5–10% w/w of the total carrier mass in a ribbon blender at 20–30 RPM for 5 min reduces agglomerate carryover to <1% w/w retained on an 850 µm screen. The finished premix is filled into 25 kg multiwall paper sacks with an inner polyethylene liner; moisture is maintained below 1.5% w/w because carbomer particles absorb ambient moisture above 60% RH, forming a surface gel film that delays dissolution. When the premix is added to the final drinking water tank at 0.5–2.0 g/L, the buffered salts raise the ionic strength, but the carbomer still hydrates within 60–90 min under mechanical agitation. The final solution is checked for viscosity at 25°C and pH 6.8–7.2; if pH is below 6.0, the polymer remains partly collapsed and the active pharmaceutical ingredient sedimentation rate increases. The premix is also tested for blend uniformity according to Ph. Eur. 2.9.40; acceptance limits are 90–110% of the declared active content for the first and final 10% of the batch discharge.
| Dosage form | Typical use level | Critical process variable | Primary standard |
|---|---|---|---|
| Oral solution/drinking water | 0.15–0.40% w/w | pH 6.8–7.4 after neutralisation | Ph. Eur. 2.2.8; Ph. Eur. 2.2.3 |
| Injectable suspension | 0.2–0.5% w/v | Terminal sterilisation vs viscosity loss | USP <71>; USP <85> |
| Tablet/bolus | 5–15% w/w | Loss on drying 1.5–2.5% w/w | USP <1216>; USP <905> |
| Capsule multiparticulates | 5–10% w/w | Granule moisture 1.0–2.0% w/w | USP <711> |
| Dry powder for reconstitution | 0.2–0.6% w/w | Powder moisture <1.5% w/w | Ph. Eur. 2.6.12 |
| Granules | 1–3% w/w | D90 below 850 µm | Ph. Eur. 2.9.12 |
| Premix | 0.05–0.25% w/w | Blend uniformity 90–110% | Ph. Eur. 2.9.40 |
Competitive Cabopol Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8618963613625 or mail to sales10@sinochem-nanjing.com.
We will respond to you as soon as possible.
Tel: +8618963613625
Email: sales10@sinochem-nanjing.com
Get Free Quote of Ascent Petrochem Holdings Co., Limited
Flexible payment, competitive price, premium service - Inquire now!
- Cabopol Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is manufactured under an ISO 9001 quality system and complies with relevant regulatory requirements.
- COA, SDS/MSDS, and related certificates are available upon request. For certificate requests or inquiries, contact: sales10@sinochem-nanjing.com.
Cabopol Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a cross-linked polyacrylic acid carbomer supplied as a free-flowing white to off-white powder and released under veterinary medicinal product raw-material controls. The trade designation does not imply pharmacological activity; the product functions as a matrix former, suspending agent, and release modifier. Compendial alignment is available with the USP/NF carbomer monographs and, where required, Ph. Eur. carbomer monograph. Release documentation includes infrared identification, carboxylic acid content 56.0%–68.0% on the dried basis, loss on drying ≤ 2.0%, sulphated ash ≤ 1.0% for unneutralised grades and ≤ 4.0% for potassium-neutralised variants, heavy metals ≤ 20 ppm under USP <231>, and residual solvent values depending on polymerisation solvent. Apparent viscosity is measured on a 0.5% w/v neutralised dispersion at 25 °C using USP <911> or Ph. Eur. 2.2.8 rotational viscometry. The grade designation determines the target viscosity range and extraction-solvent profile: Cabopol 940 and 941 are general-purpose high- and low-viscosity thickeners; Cabopol 934P is intended for oral and mucosal matrices with residual benzene controlled to ≤ 2 ppm; Cabopol 971P and 974P are provided with reduced residual-solvent profiles for injectable and low-peroxide applications.
| Parameter | Typical boundary | Reference method |
|---|---|---|
| Carboxylic acid content | 56.0%–68.0% dried basis | USP/NF Carbomer Monograph |
| Loss on drying | ≤ 2.0% | USP <731> |
| Sulphated ash | ≤ 1.0% or ≤ 4.0% | USP <281> |
| Heavy metals | ≤ 20 ppm | USP <231> |
| Residual benzene, 934P | ≤ 2 ppm | USP <467> |
| Apparent viscosity, 0.5% w/v, 25 °C | 4,000–60,000 mPa·s depending grade | USP <911> |
| pH, 1% w/v aqueous dispersion | 2.5–3.5 | Ph. Eur. 2.2.3 |
What Limits Direct Compression Use of High-Viscosity Grades in Tablets and Capsules?
Direct compression of unmodified high-viscosity Cabopol 940 is restricted by cohesive flow and electrostatic adhesion to punch faces. On a rotary tablet press operating above 25 rpm feed-frame speed, the powder tends to form a static-charged layer on the lower punch, causing weight variation. The angle of repose for ungranulated carbomer typically exceeds 40°, and bulk density may be below 0.25 g/cm³ unless densified. Pre-blending with colloidal silicon dioxide at 0.5–2.0% w/w reduces electrostatic build-up but does not eliminate the need for granulation in most formulations. Capsule filling on dosator or tamping-pin machines also requires slugging, dry granulation, or wet granulation to control fill weight. In wet granulation, the carbomer is dry-mixed with lactose monohydrate or microcrystalline cellulose before addition of water or hydroalcoholic fluid. Neutralising agents are withheld until granule formation is complete; early addition of sodium hydroxide or potassium hydroxide causes local gelation and high torque in high-shear mixers. For sustained-release tablets, the hydrated and neutralised polymer forms a gel barrier that retards drug diffusion; the matrix must contain an adequate water-soluble filler to prevent over-compression and cracking. Published production-scale data for Cabopol-specific continuous twin-screw granulation is limited; comparable carbomer grades have been processed on twin-screw extruders with L/D 40:1 at barrel temperatures below 40 °C, but process qualification is product-specific.
Viscosity Grades and Monograph Boundaries for Suspending Agents
Cabopol 940 is selected when maximal yield stress is needed for oral pastes and drench suspensions containing insoluble actives. A neutralised 0.5% w/v dispersion of 940-grade material should fall within 40,000–60,000 mPa·s at 25 °C. Cabopol 941 produces lower viscosity, typically 4,000–11,000 mPa·s, and is used when the finished formulation must remain pourable or pumpable. Cabopol 934P has a monograph viscosity range of 30,500–39,400 mPa·s and the residual benzene boundary that permits oral and mucosal use. Cabopol 971P and 974P are selected for injectable or low-solvent applications; their monomer and solvent levels are controlled to tighter limits than standard 940/941 grades. The release ranges are monograph criteria, not formulation targets after electrolyte addition. Sodium chloride above 0.1 M compresses the ionic double layer and reduces viscosity by shielding the carboxylate charges; multivalent cations can cause insolubilisation. A formulation intended for saline-containing oral rehydration solutions should be designed using a higher carbomer concentration or a salt-tolerant co-thickener, and the final rheology should be tested at the intended ionic strength.
For powders, granules, and premixes, Cabopol is incorporated at 0.1–2.0% w/w as a stabiliser and wetting modifier. The powder is pre-blended with carriers such as lactose monohydrate, dextrose, or microcrystalline cellulose before addition of active pharmaceutical ingredients; this staged blending prevents concentrated carbomer pockets that hydrate into fish-eye agglomerates. In feed premixes intended for oral administration via drinking water, the grade is usually Cabopol 941 because higher-viscosity grades generate an excessively thick suspension at the same concentration. Dry premixes are screened through a 500 µm or finer mesh before final packaging to break storage-induced lumps. For powders for reconstitution, the neutraliser is added as a dry ingredient; when water is added, the polymer hydrates and thickens during mixing. Final pH is normally adjusted to 6.0–8.0 to achieve full rheology. If the product is reconstituted as a solution, the carbomer content must be below the gel threshold; the term “solution” in this product line refers to clear-to-slightly hazy polymer systems after neutralisation, not true molecular solutions of active substances. High-humidity storage above 60% RH can reduce flow and increase lumping; opened containers should be retested for loss on drying before use.
When Terminal Sterilisation Is Applied to Injectable Suspensions Containing Carbomer
Moist-heat terminal sterilisation at 121 °C for 15 min reduces the apparent viscosity of neutralised carbomer dispersions because thermal energy disrupts hydrogen bonding and polymer entanglement. Viscosity recovery occurs during cooling but is not immediate; formulations may require 24–48 h at controlled room temperature before release viscosity returns to pre-autoclave levels. In phosphate-buffered injectable vehicles above 0.05 M, autoclaving can induce syneresis and particle settling, so buffer concentration should be kept below that boundary or alternative buffers should be tested. Aseptic filtration of carbomer dispersions is generally not feasible above 100 mPa·s; the practical manufacturing route for heat-sensitive actives is sterile filtration of the drug solution followed by aseptic incorporation into pre-sterilised carbomer gel. Injectable grades must meet bacterial endotoxin limits of ≤ 0.5 EU/mg or the finished-product limit, whichever is lower; endotoxin testing is necessary because the polymer can bind but not eliminate endotoxin. Residual benzene for injectable grade should be not more than 1 ppm unless the product’s permitted daily exposure under ICH Q3C supports a higher value. The supplier’s release data for residual acrylate monomers and polymerisation solvents should be reviewed against Ph. Eur. 5.2.8 or USP <467> before use in parenteral veterinary products.
Compared with unmodified polyacrylic acid, cellulosic excipients, and polysaccharide suspending agents, Cabopol Veterinary Grade API differs in charge density, neutralisation response, and electrolyte sensitivity. Hypromellose and hydroxyethylcellulose thicken without neutralisation and tolerate higher ionic strength, but they do not provide the same high yield stress at low addition levels and may require preservatives against microbial growth. Xanthan gum is pseudoplastic and salt-tolerant but can introduce bioburden variability and proteinaceous impurities. Unmodified polyacrylic acid has lower molecular weight and lower thickening efficiency; achieving similar yield stress may require 2–5 times the concentration. Polycarbophil, a related cross-linked polyacrylic acid, offers higher bioadhesion for mucosal veterinary delivery but is not automatically interchangeable with carbomer in injectable or ophthalmic formulations because its residual solvent and hydration profiles differ. Cabopol’s anionic carboxyl groups interact with cationic drugs, cationic surfactants, and polyvalent cations; this can cause precipitation or viscosity collapse if the cationic component is added before hydration and neutralisation.
Managing Neutralisation Sequence Conflicts in High-Shear Wet Granulation
High-shear wet granulation of carbomer-containing formulations is most stable when neutralisation occurs after granule formation. Addition of sodium hydroxide solution during the water addition phase produces a rapid viscosity increase that can exceed the torque limit of the impeller; on a 100 L high-shear granulator, premature neutralisation can raise power consumption to 70–90% of motor load and produce non-uniform granules. The preferred sequence is water or hydroalcoholic granulation, wet massing to the desired endpoint, and subsequent addition of the neutraliser as a dilute solution. Alternatively, pre-neutralised grades may be used, but the resulting hydrated gel is less free-flowing and can adhere to dryer walls in fluid-bed units. Granule drying should be controlled below 60 °C inlet air temperature for unneutralised carbomer; higher temperatures can cause surface crusting without increasing drying rate. Milling after drying should use low-shear mills or screens to avoid excessive fines and static charge. The neutralisation endpoint is not simply pH 7.0; the target pH for maximum viscosity is usually 6.0–8.0, but the exact value depends on electrolyte content and grade.
Low-humidity compounding suites with relative humidity below 20% can increase electrostatic charging of carbomer powder. Transfer through ungrounded flexible hoses or centrifugal sifters can generate dust and static discharge. Process equipment should be bonded and grounded; addition rates should be controlled to keep dust concentration below combustible dust thresholds. The powder should not be stored in open hoppers in high-temperature zones above 40 °C, because thermal cycling can promote moisture migration and agglomeration. For continuous blending lines, loss-in-weight feeders with aggressive agitation are not recommended; a twin-screw feeder with a fine-pitch auger and low hopper vibration provides more consistent feed. If the powder is conditioned with a flow aid, the flow aid should be pre-blended in small batches to avoid segregation. These handling constraints are independent of the final dosage form and apply to tablets, capsules, powders, granules, and premix production.
| Dosage form | Typical Cabopol grade | Function | Critical boundary |
|---|---|---|---|
| Tablets | 971P, 974P | Matrix former / binder | Neutralise after granulation to avoid high torque |
| Injections | 974P, sterile-grade carbomer | Suspending agent | Endotoxin ≤ 0.5 EU/mg; terminal autoclave viscosity loss |
| Capsules | 934P | Controlled-release matrix | Moisture exposure above 60% RH requires pre-drying |
| Powders / granules | 941, 971P | Dust binder / reconstitution stabiliser | Screen through 500 µm to remove agglomerates |
| Premix | 941 | Feed premix stabiliser | Maximum 2.0% w/w to avoid gelling in drinking water |
| Solutions | 940, 941 | Viscosity modifier | pH adjustment to 6.0–8.0 required for full thickening |
How Do Temperature, Ionic Strength, and Shear Rate Affect Oral Drench and Injectable Suspensions?
Neutralised carbomer dispersions are shear-thinning; apparent viscosity decreases with increasing shear rate and recovers when shear is removed. This property supports suspension of insoluble veterinary actives at rest while allowing passage through drench guns or injection needles. The low-shear viscosity that maintains sedimentation stability is typically characterised at 0.1–1 s⁻¹; standard release viscosity at 20 rpm or equivalent spindle speed does not fully represent this low-shear behaviour. For oral drenches, a target low-shear viscosity of 2,000–20,000 mPa·s at 0.5 s⁻¹ is often used, but the finished product should be tested under its own matrix. Temperature also affects viscosity: heating from 25 °C to 40 °C can reduce viscosity by 10–30%, depending on grade and neutralisation. Injectable suspensions should be evaluated at 2–8 °C and at room temperature to ensure the active does not settle under cold-chain storage. Ionic strength from tonicity modifiers such as sodium chloride or dextrose compresses the gel network; if the formulation requires isotonicity, the carbomer concentration should be increased and the final product tested for injectability through 21G or 23G needles. Steam sterilisation may shift pH downward; the formulation should be adjusted to maintain pH within the validated range after autoclaving.
Unopened containers should be stored below 25 °C and 60% RH. Exposure to humid air above 70% RH increases lump formation and reduces flow in automatic dispensing equipment. The product should not be combined with strong oxidising agents or with primary amines before hydration; premature pH shifts and local gelation can occur. For sterile veterinary preparations, the finished product must be validated for sterility according to Ph. Eur. 2.6.1 or USP <71>, and for bacterial endotoxins according to Ph. Eur. 2.6.14 or USP <85>. Release viscosity alone is not a sufficient predictor of finished suspension stability; formulation-specific rheology after addition of salts, buffers, and active ingredients should be qualified across the intended storage range.
